A randomised, double-blind active (pramipexole 0.5 mg Tid [three times daily]) and placebo controlled, efficacy study of pramipexole given 0.5 mg and 0.75 mg Bid [twice daily] over a 12-week treatment phase in early Parkinson's disease patients (PramiBID).

Trial Profile

A randomised, double-blind active (pramipexole 0.5 mg Tid [three times daily]) and placebo controlled, efficacy study of pramipexole given 0.5 mg and 0.75 mg Bid [twice daily] over a 12-week treatment phase in early Parkinson's disease patients (PramiBID).

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2013

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PramiBID
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 06 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
    • 18 Jun 2008 The expected completion date for this trial is now 1 Sep 2008 as reported by ClinicaTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top